Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 3
1990 3
1991 2
1992 9
1993 5
1994 6
1995 10
1996 13
1997 22
1998 18
1999 54
2000 86
2001 160
2002 160
2003 201
2004 286
2005 295
2006 376
2007 459
2008 642
2009 718
2010 895
2011 1014
2012 1176
2013 1338
2014 1434
2015 1516
2016 1543
2017 1644
2018 1647
2019 1738
2020 2078
2021 2348
2022 2317
2023 2380
2024 2069

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,489 results

Results by year

Filters applied: . Clear all
Page 1
Breast Cancer Treatment: A Review.
Waks AG, Winer EP. Waks AG, et al. JAMA. 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323. JAMA. 2019. PMID: 30667505 Review.
IMPORTANCE: Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. ...Local therapy for all patients w …
IMPORTANCE: Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more t …
Neoadjuvant treatment for HER2-positive breast cancer.
Takada M, Toi M. Takada M, et al. Chin Clin Oncol. 2020 Jun;9(3):32. doi: 10.21037/cco-20-123. Epub 2020 Jun 3. Chin Clin Oncol. 2020. PMID: 32527117 Free article. Review.
The addition of trastuzumab to neoadjuvant chemotherapy roughly doubles the proportion of patients with HER2-positive breast cancer who achieve pathological complete response (pCR). Patients with pCR show better prognosis compared with those with residual dis …
The addition of trastuzumab to neoadjuvant chemotherapy roughly doubles the proportion of patients with HER2-positive breast …
Treatment of breast cancer.
Maughan KL, Lutterbie MA, Ham PS. Maughan KL, et al. Am Fam Physician. 2010 Jun 1;81(11):1339-46. Am Fam Physician. 2010. PMID: 20521754 Free article. Review.
Understanding breast cancer treatment options can help family physicians care for their patients during and after cancer treatment. ...In general, node-positive breast cancer is treated systemically with chemotherapy, endocrine …
Understanding breast cancer treatment options can help family physicians care for their patients during and after ca …
Breast cancer.
Harbeck N, Gnant M. Harbeck N, et al. Lancet. 2017 Mar 18;389(10074):1134-1150. doi: 10.1016/S0140-6736(16)31891-8. Epub 2016 Nov 17. Lancet. 2017. PMID: 27865536 Review.
Primary conventional surgery is not the optimal choice for all patients any more. In triple-negative and HER2-positive early breast cancer, neoadjuvant therapy has become a commonly used option. Depending on clinical tumour subtype, therapeutic backbon …
Primary conventional surgery is not the optimal choice for all patients any more. In triple-negative and HER2-positive early breas …
Biology and Treatment of HER2-Low Breast Cancer.
Nicolò E, Tarantino P, Curigliano G. Nicolò E, et al. Hematol Oncol Clin North Am. 2023 Feb;37(1):117-132. doi: 10.1016/j.hoc.2022.08.013. Hematol Oncol Clin North Am. 2023. PMID: 36435605 Review.
Current guidelines recommend a dichotomous classification of HER2 as either positive or negative, to guide clinicians in treatment decisions. Until now, only patients with HER2-positive breast cancer (BC) had been demonstrated to derive clinical …
Current guidelines recommend a dichotomous classification of HER2 as either positive or negative, to guide clinicians in treatment …
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
Harbeck N. Harbeck N. Breast. 2022 Mar;62 Suppl 1(Suppl 1):S12-S16. doi: 10.1016/j.breast.2022.01.006. Epub 2022 Jan 19. Breast. 2022. PMID: 35148934 Free PMC article.
The availability of HER2-targeted therapy has dramatically improved patient outcome in HER2-positive (HER2+) early breast cancer (EBC) as recently demonstrated by the EBCTCTG metaanalysis on trastuzumab in HER2+ EBC: Adding trastuz …
The availability of HER2-targeted therapy has dramatically improved patient outcome in HER2-positive (HER2+) ear …
Treatment of Breast Cancer in Young Adults.
Tesch ME, Partridge AH. Tesch ME, et al. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-12. doi: 10.1200/EDBK_360970. Am Soc Clin Oncol Educ Book. 2022. PMID: 35580291 Free article.
Although breast cancer is rare and understudied in adults age 40 and younger, recent epidemiologic data show an increasing incidence of breast cancer among young women in the United States and ongoing inferior long-term outcomes. ...Ovarian function su …
Although breast cancer is rare and understudied in adults age 40 and younger, recent epidemiologic data show an increasing inc …
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP. Leon-Ferre RA, et al. BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. BMJ. 2023. PMID: 37253507 Review.
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recurrence and mortality. ...Furthermore, advances in drug development have led to the approval of antibody-drug conjugates that are redefining …
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recu …
Tumoral heterogeneity of breast cancer.
Roulot A, Héquet D, Guinebretière JM, Vincent-Salomon A, Lerebours F, Dubot C, Rouzier R. Roulot A, et al. Ann Biol Clin (Paris). 2016 Dec 1;74(6):653-660. doi: 10.1684/abc.2016.1192. Ann Biol Clin (Paris). 2016. PMID: 27848916 Free article. Review. English.
In breast cancer, inter-tumor heterogeneity was best characterized in the 2000s thanks to high throughput analyses. ...These new biological knowledge will allow us to anticipate such heterogeneity and individualize the management of breast cancer....
In breast cancer, inter-tumor heterogeneity was best characterized in the 2000s thanks to high throughput analyses. ...These n …
Breast cancer in young women.
Radecka B, Litwiniuk M. Radecka B, et al. Ginekol Pol. 2016;87(9):659-663. doi: 10.5603/GP.2016.0062. Ginekol Pol. 2016. PMID: 27723074 Free article. Review.
Breast cancer (BC) in young women is rare, affecting only 4-6% of women under the age of 40. ...Surgical management includes mastectomy or breast-conserving surgery, followed by radiation therapy (younger women have higher local recurrence rates than o …
Breast cancer (BC) in young women is rare, affecting only 4-6% of women under the age of 40. ...Surgical management includes m …
25,489 results
You have reached the last available page of results. Please see the User Guide for more information.